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Objective: We compared 3 different decellularization protocols in porcine heart
valves for efficiency of complete cell removal and potential for recellularization.
Methods: Porcine aortic and pulmonary roots were treated with trypsin, sodium-
dodecyl-sulphate, or a new method using 0.25% tert-octylphenyl-polyoxyethylen in
combination with sodium-deoxycholate. After a subsequent ribonuclease digestion,
specimens were seeded with in vitro expanded human saphenous vein endothelial
cells and myofibroblasts.
Results: After treatment with trypsin and subsequent ribonuclease digestion, endo-
thelial attachment took place; however, xenogenic cells were still visible within the
matrix. Unexpectedly, when human cells were seeded onto specimens that had been
decellularized with sodium-dodecyl-sulphate, the matrices were surrounded by
nonviable endothelial cell fragments, indicating a toxic influence of the ionic
detergent; 0.25% tert-octylphenyl-polyoxyethylen together with sodium-deoxy-
cholate completely removed porcine cells and enabled host recellularization.
Conclusion: Compared with trypsin and sodium-dodecyl-sulphate involving decel-
lularization procedures, reported to be effective in cell removal and susceptible to
recellularization with human cells, only the porcine matrix treated with a new
detergent-based decellularization method using 0.25% tert-octylphenyl-polyoxyeth-
ylen/sodium-deoxycholate followed by nuclease digestion presented an excellent
scaffold for recellularization with human cells.
Valvular heart disease is an important cause of morbidity andmortality. Currently available prostheses are associated with ma-jor limitations. Mechanical valve substitutes require lifelong an-ticoagulation, can cause serious thromboembolic and bleedingcomplications, and are susceptible to infection.1 Although bio-prosthetic heart valves have proved clinically successful over the
short term, their long-term performance needs improvement.2,3
Human allografts eliminate the need of anticoagulation and have the best hemo-
dynamic properties, but their availability is limited. None of these currently used
heart valve substitutes shows any growth potential or regeneration capability, which
would play an important role especially in the treatment of pediatric patients.
Tissue engineering of heart valves is a multidisciplinary approach to overcome
these limitations. The created autologous living replacement structure should have
the ability to self-repair, remodel, and thereby increase durability without the risk of
rejection and ideally even grow.
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The initial and crucial step is to obtain an optimal valve
matrix.4,5 We have chosen the concept of using a decellu-
larized xenogenous heart valve.
The aim of this study was to test different decellulariza-
tion protocols for their efficiency of complete cell removal
and ability to produce a matrix with excellent recellulariza-
tion susceptibility with human cells.
Material and Methods
Decellularization of Porcine Heart Valve Tissue
Porcine pulmonary (PV; n  16) and aortic heart valve conduits
(AV; n  14) were obtained from a local slaughterhouse and
excised of adherent fat and myocardium. For comparison with
native untreated valves a root specimen and 1 leaflet of each
conduit were excised and further processed for scanning electron
microscopy (SEM) and laser scanning microscopy (LSM). The
heart valves were incubated for 24 hours with a solution containing
multiple antibiotics for sterilization.
Three different decellularization protocols were used for com-
parison, of which 2 have been described5-8 and the third was
developed in our laboratory, using 2 detergents formerly used for
cell extraction9 in combination with ribonuclease digestion and to
our knowledge has not been published before.
In the first group the valve conduits (PV  5, AV  4) were
treated with 0.1% trypsin (Gibco, Paisley, Scotland, UK) with
0.02% ethylenediaminetetraacetic acid (EDTA; Merck, Darmstadt,
Germany) in phosphate-buffered saline solution without Ca2 and
Mg2 (PBS/, Gibco) for 48 hours. In the second group valve
conduits (PV  4, AV  3) were treated with 0.1% sodium-
dodecyl-sulphate (SDS; BioRad, Hercules, Calif) in PBS/ for
24 hours. Treatment in group 3 (PV  7, AV  7) is a detergent-
based decellularization mixture consisting of a 24-hour incubation
period with 0.25% tert-octylphenyl-polyoxyethylen (Triton X-100,
BioRad) plus 0.25% sodium-deoxycholate (Merck) in PBS/ at
37°C, followed by a intensive wash cycle with M-199 medium
(Gibco) for 72 hours at 4°C to remove residual substances. All
specimens were subsequently treated by a nuclease digestion with
ribonuclease (100 g/mL; RNase, Roche Diagnostics Gmbh,
Mannheim, Germany) and deoxyribonuclease (150 IU/mL;
DNase, Sigma, St Louis, Mo) with 50 mmol/L MgCl2 in PBS/
for 24 hours at 37°C to remove remaining nucleic remnants.
Samples were again washed with M-199 medium for 24 hours at
4°C. All steps were conducted under continuous shaking.
Cell Separation and Expansion
Human saphenous vein endothelial cells (HSVEC) were harvested
from discarded segments of vena saphena magna of patients un-
dergoing coronary artery bypass surgery. In brief, the veins were
cannulated and flushed with sterile PBS/ under sterile condi-
tions. The lumen was then filled with 0.2% collagenase type II
(Gibco) solution and left at room temperature for 15 minutes. To
dislodge the loosened endothelial cells the vein was gently mas-
saged and flushed with M-199 medium. The HSVEC were pelleted
by centrifugation for 5 minutes at 300g and thereafter resuspended
in culture medium consisting of M-199 medium, 20% pooled
human serum, 100 g/mL heparin (Sigma), 100 U/mL penicillin,
and 100 g/mL streptomycin (Gibco) and 30 mg/L endothelial cell
growth supplement (Upstate, Lake Placid, NY).10 The cell suspen-
sion was transferred to a 25-cm2 culture flask. Endothelial cells
were maintained in a humidified incubator at 37°C and 5% CO2
and the culture medium was changed every fourth or fifth day.
Confluent HSVEC were detached using 0.05% trypsin/EDTA in
PBS/ and subcultured. Purity of cells was evaluated by factor
VIII (FVIII: vWF) staining,11 transmission electron microscopy
(presence of Weibel-Pallade bodies), and expression of CD62E
(E-selectin). No contamination by myocytes or fibroblasts was
detected.
The remaining vessel was minced and pieces of 1 to 2 mm2
were placed into a 25-cm2 culture flask with myofibroblast culture
medium containing Dulbeco’s modified Eagle’s medium (Bio-
Whittaker Europe, Verviers, Belgium), 100 U/mL penicillin, and
100 g/mL streptomycin until saphenous vein media cells grew
out onto the surface of the culture flask. Confluent cell cultures
were subcultured with 0.05% trypsin/EDTA in PBS/.
Cell Seeding
The seeding susceptibility of the 3 differently decellularized por-
cine heart valve matrices was compared without any pretreatment
of the matrices. Each valve conduit was divided and leaflets were
dissected. Two 100-mm2 specimens of the pulmonary or aortic
root, as well as 2 leaflets of each conduit, were placed into a
culture dish and seeded under static conditions with either 1 
104/mm2 HSVEC or 2  104/mm2 saphenous vein myofibroblasts
(only HSVEC were seeded onto SDS-treated specimens). After-
ward, the specimens were incubated in a humidified environment
at 37°C and 5% CO2 either for 5 days (HSVEC) or 10 days
(myofibroblasts).
Biocompatibility of SDS Treatment
To examine a possible toxic influence of SDS released from
decellularized specimens, increasing concentrations (10%-30%
v/v) of PBS/, used to store the SDS-treated root specimens,
were added to culture medium of in vitro cultured endothelial cells
(EC) and compared with the influence of PBS/ that was not
used for storing specimens.
Morphological Analysis
The specimens were either fixed by immersion in 2.5% glutaral-
dehyde for at least 24 hours and further processed for SEM or
embedded in Tissue Tek OCT Compound (Sakura, Zoeterwoude,
The Netherlands). Five cryostat sections (10 m) of each specimen
were stained for the production of von Willebrand factor (anti-
vWf, Serotec, Du¨sseldorf, Germany) to analyze the viability of the
transplanted HSVEC. The DNA-specific dye TO-PRO 3 (Molec-
ular Probes, Leiden, The Netherlands) was used to assess the
removal of xenogenous cells or nuclei in the porcine matrix.
The sections were also stained with an anti-porcine collagen
type I and III antibody (Monosan, Uden, The Netherlands), shown
to be cross-reactive with human type I/III collagen, and with an
anti-elastin antibody (monoclonal anti-elastin, Clone BA-4,
Sigma) to examine structural alterations of the matrix fibers.
Cryostat section was scanned for remaining cell remnants with
a Zeiss LSM 510 laser scanning microscope (Zeiss, Jena, Ger-
many) using the 3-dimensional analysis mode and representative
micrographs are shown.
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Results
Electron microscopic examination of the group 1 matrix
specimens (n  36) treated with trypsin/EDTA demon-
strated the typical cobblestone morphology of a completely
confluent endothelial cell monolayer (n  18, Figure 1, A,
B). The venous media cells attached to the surface of the
xenogenous tissue in a patchy distribution (n  18, not
shown). Confocal microscopic examination revealed viable
EC staining positive for vWf, as these appeared as thin,
bright, confluent red layer on the surface of the pulmonary
and aortic wall as well as on the leaflets. It appeared that the
media cells started to synthesize collagen. However, porcine
cells were still detectable in the matrix after decellulariza-
tion (Figure 2, A, B).
When human cells were seeded onto SDS-treated pul-
monary or aortic root specimens (Figure 2, C) in group 2 (n
 14), no cell attachment took place but a massive cell lysis
was observed within 24 hours of incubation. On examining
the leaflets (n  14), a patchy distribution (n  8) or cell
lysis (n  6) of HSVEC could be seen but no confluence
was reached even after 5 days of incubation.
Increasing concentrations (10%-30%) of PBS/, used
to store the SDS-treated root-specimen, added to culture
medium of in vitro cultured HSVEC revealed a decreasing
amount of attached and viable endothelial cells in the cul-
ture flasks within 24 hours. In contrast, the same amount of
PBS/ that was not used for storage of SDS-treated spec-
imens did not affect in vitro cell growth (Figure 3, A to
D). This test for the biocompatibility of SDS treatment
indicates that not even a prolonged washout of SDS
removes residual ionic-detergent substances within root
matrices.
The seeding of porcine heart valve tissue in the third
group (n  56) treated with Triton X-100 plus sodium-
deoxycholate followed by incubation with RNAse/DNAse
and an extensive washing procedure with M-199 medium
resulted in a confluent HSVEC layer (n  28) as was
already described for group 1 (Figure 1, C).
The TO-PRO 37 staining in the sections examined dem-
onstrated no visible cells within the porcine pulmonary (n
28) as well as aortic valve matrix (n  28) (Figure 2, D).
Confocal microscopic examination of specimens seeded
with media cells demonstrated the thin, bright green colla-
gen-specific area surrounding the patchy attached human
myofibroblasts illustrating viable and actively collagen pro-
ducing cells. A representative micrograph is shown in Fig-
ure 4.
Discussion
One approach to obtain scaffold material for tissue engi-
neering of heart valves is to use allogenic or xenogenic
material that is decellularized. These matrices should
present an appropriate scaffold on which recipient autolo-
gous cells could be seeded.
Currently used glutaraldehyde cross-linked valves are
mostly of porcine origin,2 though different reports accord-
ing xenogeneic rejection patterns12-14 will need further in-
vestigation. Viral-associated risks15-17 should be considered
when xenogenous tissue is used for tissue engineering. This
was a reason to involve ribonuclease digestion within a
decellularization procedure. Due to the limited availability
Figure 1. A, Native porcine aortic root (monolayer of endothelial
cells); SEM 750. B, Porcine aortic wall after treatment with
trypsin for 48 hours and seeded with in vitro expanded EC; SEM
750. C, Porcine aortic wall treated with Triton X-100/sodium-
deoxycholate and ribonuclease digestion. Seeded with expanded
EC; SEM 750.
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of human autologous heart valves the use of xenogenic
valves is still of obvious advantage. Because vascular grafts
placed in humans do not spontaneously form an endothelial
monolayer, whereas they do in animals,18 the importance of
a confluent and viable endothelial cell layer on valve sub-
stitutes prior to implantation seems essential compared with
other approaches.14,19 Seeding of vascular grafts with hu-
man autologous endothelial cells improves their long-term
patency20,21 and reduces the thrombogenicity of cardiovas-
cular implants.22
The recipient saphenous vein is an easily accessible cell
source for seeding decellularized valves prior to implanta-
tion. Early experiments comparing allogenic and autologous
cells favored the latter.23 The use of artery segments24 is
unlikely to be transferable to the clinical situation.
Several decellularization methods involving detergents
and/or enzymatic digestion have been described previously
with some success but only very few reports have dealt with
their susceptibility to seeding leaflet as well as root matri-
ces.
In this study we demonstrate that the decellularization
method of xenogenous heart valves is a crucial feature to
obtain the optimal matrix for a tissue-engineered valve
substitute. We found considerable differences in regard to
the efficiency of complete xenogenous cell removal and the
susceptibility to human cell attachment.
We as others found using trypsin5 or a nonionic detergent
like Triton X-100 followed by ribonuclease digestion25 re-
vealed only an incomplete removal of cells. Bader and
colleagues5 described that a longer incubation with trypsin
Figure 2. A, Native porcine aortic wall, staining for collagen I and III (green), elastin (red), and DNA (white); LSM
400. B, Group 1, porcine aortic wall after treatment with 0.1% trypsin, staining for collagen I and III (green),
elastin (red), and DNA (white); LSM 400. C, Porcine aortic wall after treatment with 0.1% SDS, staining for
collagen I and III (green), elastin (red), and DNA (white); LSM 400. D, Porcine aortic wall after treatment with
0.25% Triton X-100/0.25% sodium-deoxycholate and nuclease digestion seeded with human EC, staining for vWF
(red), collagen I and III (green), elastin (red), and DNA (white); LSM 400.
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might be more effective in cell removal but causes a dis-
ruption of the matrix bundles. However, residual cells and
cell remnants within the matrix might lead to calcification.12
As the naturally occurring alpha-gal antibodies in humans
are interacting with alpha-gal epitopes26 on porcine cells,
the efficient extraction of xenogenous cells is crucial. Oth-
erwise an acute immunogenic response and early graft fail-
ure will follow.19
Figure 4. Collagen synthesis of myofibroblasts seeded onto porcine heart valve matrix treated with 0.25% Triton
X-100/0.25% sodium-deoxycholate and nuclease digestion, staining for collagen I and III (green), elastin (red), and
DNA (white); LSM 400.
Figure 3. Increasing concentrations (10%-30% v/v) of PBS/ that was used to store SDS-treated specimens added
to culture medium of in vitro cultured EC; light microscopy40. (A) 10%, (B) 20%, (C) 30%, (D) negative control (30%
of PBS/ that was not used to store SDS-treated specimens added to culture medium).
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SDS treatment has previously been used to obtain com-
plete acellularity7 but was also reported to destabilize the
collagen triple helical domain and to swell the elastin net-
work.9,27 However, these studies did not describe the seed-
ing susceptibility. SDS is still described to be efficient for
leaflet decellularization8 and was recently presented to be
compatible for seeding of leaflets with endothelial cells.28
Although in our study SDS produced a biological matrix
free of any visible xenogenous cells, it was impossible to
seed the porcine aortic or pulmonary root specimens with
human endothelial cells or myofibroblasts, as massive cell
lysis occurred within 24 hours of incubation. This contro-
versial finding might be due to probably higher levels of
residual SDS remaining in the vascular wall. When increas-
ing amounts of PBS/, which was used to store the SDS
decellularized valve matrix after several days of washing,
were added to culture medium of HSVEC, cell lysis oc-
curred.
The findings of Kim and colleagues28 with respect to the
seeding of leaflets might be explainable by the fact that the
washing procedure is more effective when treating the much
thinner valve leaflets. Because in a clinical setting the com-
plete valve conduit will likely be used, the observation made
by us seems crucial with respect to further studies involving
SDS.
Our decellularization procedure, involving the combina-
tion of Triton X-100 and sodium-deoxycholate followed by
a washing process with M-199 medium to remove any
residual detergents and an enzymatic digestion with
DNAse/RNAse to remove remaining nucleic acids, results
in an excellent scaffold, free of any histologically detectable
xenogenous cells or cell remnants, which is well suited for
seeding with human cells. Transplanted endothelial cells
and myofibroblasts remained viable. We could even dem-
onstrate active collagen synthesis by human myofibroblasts
attached to the xenogenous matrix. Although Triton and
cholate treatment was presented not to affect the structural
integrity of either elastin and collagen,9 further studies
concerning mechanical testing are currently under investi-
gation in our laboratory. Cell seeding under flow conditions
should not have impact on the biocompatibility of xenog-
enous matrices, but cultivation under shear stress will pro-
vide the ability of proper adherence of seeded cells to
acellular matrix surface and is also subject of current ex-
periments.
We conclude from our findings that decellularization
procedures used differ considerably in their efficiency of
cell removal and susceptibility of the matrix to recellular-
ization. Our newly developed method produces an excel-
lently preserved xenogenic scaffold that fulfills both re-
quirements, acellularity and high susceptibility to
recellularization with human vascular cells.
We thank Anneliese Nigisch, Birgitta Winter, Eva Eichmair,
Barbara Dekan, and Sabine Lehner for their excellent technical
assistance.
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